Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Prevention of acute sickle cell crisis: review of the NEJM report
source: Practical Pain Management
year: 2016
authors: Leonard Goldstein, Victoria A. Troncoso, Roya Vahdatinia
summary/abstract:A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab, a novel pharmaceutical agent currently in pipeline development by Selexys Pharmaceuticals.
The drug, designed to block the underlying mechanism of acute painful crisis in patients suffering from sickle-cell disease, could be one of the first and most effective medications of its kind. For all the details on the Phase 2 research, read the original Practical Pain Management report.
In this commentary, Leonard B. Goldstein, DDS, PhD, and colleagues review the research and provide their own opinion on the prospect of a novel pharmaceutical agents for patients suffering from sickle cell disease.
read more
+myBinderRelated Content
-
Successful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
-
Only 21% of Kids with ADHD and SCD Are Treated for Attention DeficitA study of children with sickle cell dis...
-
Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCDGlycoMimetics, in collaboration with Pfi...
-
The Role of Sleep Impairments on Pain Severity in Adults With Sickle Cell DiseaseSleep is a complex process and impairmen...
-
Don’t Let Sickle Cell Disease Limit Youhttps://www.onescdvoice.com/wp-content/u...
-
Oral Manifestations of Sickle Cell DiseaseSickle cell disease is one of the most c...
-
The Cadre (Coeur Artères et Drépanocytose) study- heart arteries and sickle cell diseaseEach year, more than 230,000 children...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.